中医辨证疗法联合埃克替尼治疗晚期非小细胞肺癌疗效观察

发布时间：2018-03-18 22:47

本文选题：辨证论治　切入点：埃克替尼　出处：《中国中西医结合杂志》2017年09期 　论文类型：期刊论文

【摘要】：目的观察中医辨证疗法联合埃克替尼治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法 60例晚期NSCLC按随机数字表分为治疗组和对照组,每组各30例,治疗组予中医辨证联合埃克替尼,对照组单用埃克替尼,治疗至疾病进展或出现不可耐受的不良反应。统计分析两组治疗4周后总有效率、疾病控制率、生活质量(EORTC QLQ-C30及QLQ-LC13量表)、体力状况评分、不良反应、中医证候积分,并计算疾病无进展生存期(PFS)。结果与对照组比较,治疗组PFS延长(337 dvs.238 d,P=0.028);治疗后EORTC QLQC30量表躯体功能、总健康状况及经济困难评分升高(P0.05),疲倦、疼痛、气促、失眠、食欲减退及腹泻评分降低(P0.05),QLQ-LC13量表气促、咳嗽及胸痛评分降低(P0.05);在总有效率和疾病控制率、体力状况评分、不良反应方面,治疗组较对照组有改善的趋势,但差异无统计学意义(P0.05)。结论应用埃克替尼联合中医辨证治疗晚期NSCLC可延长PFS,改善生活质量和中医证候。
[Abstract]:Objective to observe the therapeutic effect and side effects of traditional Chinese medicine (TCM) combined with ectinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 60 patients with advanced NSCLC were randomly divided into treatment group (n = 30) and control group (n = 30). The treatment group was treated with traditional Chinese medicine syndrome differentiation combined with Ektinib, the control group was treated with Ektinib alone, and the disease progression or unbearable adverse reactions occurred in the control group. The total effective rate and disease control rate of the two groups after 4 weeks of treatment were statistically analyzed. The quality of life (QOL) was evaluated by orTC QLQ-C30 and QLQ-LC13 scale, physical status score, adverse reaction, TCM syndrome score, and progressive survival time were calculated. Results compared with the control group, the PFS in the treatment group was prolonged to 337#en3# dP0. 028%, and the somatic function of EORTC QLQC30 scale was increased after treatment. The scores of total health status and economic difficulties increased P0.05, tiredness, pain, shortness of breath, insomnia, loss of appetite and decreased score of diarrhea. P0.05 scores of QLQ-LC13, cough and chest pain decreased (P0.05). The adverse reactions in the treatment group were improved compared with the control group, but the difference was not statistically significant (P 0.05). Conclusion the application of Ektinib combined with TCM syndrome differentiation can prolong the NSCLC, improve the quality of life and TCM syndromes.
【作者单位】：上海中医药大学附属龙华医院肿瘤六科;浙江省永嘉县中医院内科;上海交通大学附属胸科医院肿瘤科;
【基金】：上海市科学技术委员会科研计划项目(No.13401905100) 上海市卫生和计划生育委员会科研课题(No.201440436)
【分类号】：R734.2

【相似文献】